Another study developed a Napabucasin-based STAT3 PROTAC XD2-149, which inhibited STAT3 signaling in pancreatic cancer cell lines, but did not induce proteasome-dependent STAT3 degradation, suggesting that targeting STAT3 degradation remains challenging (Hanafi, Chen, & Neamati, 2021). This evidence concerns the gene STAT3 and familial pancreatic carcinoma.